Eileen A. Liu
Consumer Safety Officer / Investigator
FDA San Francisco District Office (Alameda, CA)
International investigator with 20 483s across 12 countries — known for uncovering systemic data integrity failures, method validation gaps, and aseptic processing deficiencies. Led the Eugia Pharma investigation that exposed falsified EM records across multiple operators.
Inspection Approach
How Eileen Inspects
Liu conducts methodical, documentation-intensive inspections that trace discrepancies through the entire quality system — from batch records to deviation investigations to CAPA effectiveness. She is particularly skilled at detecting data integrity failures, having led the Eugia Pharma inspection where operators admitted to updating batch records for sampling, testing, and cleaning that was never actually performed.
A distinctive feature of her approach is scrutiny of method validation. At Cipla Verna, she flagged that multiple test methods — both in-house and compendial — lacked documented validation, verification, or transfer records. This focus on method validation specificity is a relatively newer enforcement pattern that many facilities are not prepared for.
She also conducts detailed physical observations of aseptic operations. At NerPharMa in Italy, she identified that operators used goggles with numerous open holes exposing skin during filling line setup — a finding that reflects her attention to personnel gowning interfaces and contamination pathways that are easily overlooked during routine self-inspections.
Citation Patterns
Top Focus Areas
Inspection History
Notable Inspections
NerPharMa S.r.l.
- Aseptic operators used goggles with numerous open holes, exposing skin during filling line setup and aseptic processing
- Insufficient space to place active air samplers in representative locations within the EM system
- Non-viable particle monitoring probes not placed in representative Grade A areas
- Deficient cleaning and disinfection procedures for aseptic processing areas
- Integrity testing deficiencies observed during live demonstration
Cipla Ltd.
- Multiple test methods (in-house and compendial) not validated, verified, or transferred appropriately for drug products, APIs, and in-process samples
- Cleaning and disinfecting procedures for aseptic areas inadequate
- Failure investigations for deviations were incomplete
- Computer system controls insufficient — audit trail gaps
Eugia Pharma Specialities Limited
- Operators admitted to updating batch records for sampling, testing, and cleaning that was never actually performed
- Falsified environmental monitoring records for ISO 5 and ISO 7 areas across multiple aseptic filling lines
- Non-viable particle counts recorded from different times/locations and altered to match batch records
- Systemic data integrity failures involving numerous production and QA staff over multiple months
Shilpa Medicare Limited
- Sterile injectables manufacturing deficiencies leading to import alert
- Aseptic processing and contamination control failures
Grifols Diagnostic Solutions Inc.
- Diagnostics manufacturing quality system deficiencies
- Documentation and process control gaps
Pre-Inspection Preparation
How to Prepare
- 1 Audit all deviation investigation records for completeness — Liu traces deviations through root cause to CAPA effectiveness. Superficial "operator error" conclusions will be challenged.
- 2 Verify every test method (including compendial) has documented validation, verification, or transfer records specific to your facility. This is an active focus area she pursues aggressively.
- 3 Review environmental monitoring programmes for proper placement of active air samplers and non-viable particle monitors in representative Grade A locations.
- 4 Conduct a data integrity self-assessment focusing on EM records, batch record entries, and whether all documented activities were actually performed.
- 5 Ensure aseptic gowning is complete with no exposed skin — goggles, gloves, and gown interfaces will be examined closely during live observations.
- 6 Prepare cleaning and disinfection records for aseptic areas with validated procedures and documented efficacy.
- 7 Have computer system validation documentation readily accessible, including audit trails and access controls for LIMS and batch record systems.
- 8 Review training records for currency and specificity — Liu verifies that operator training covers the actual procedures being performed, not just generic topics.
- 9 Ensure batch record review processes catch discrepancies before product release — she checks whether the QC unit fulfilled its 211.22 review responsibilities.
- 10 If you have had a previous 483 or warning letter, document comprehensive corrective actions with objective evidence of sustained effectiveness.
Commonly Cited Regulations
Top CFR Citations
Frequently Paired With
Co-Investigators
Geographic Reach
Download Eileen A. Liu — FDA Investigator Profile
Enter your details once to unlock all Audit Hub resources. All future downloads are instant.
Leucine is the first AI-native platform built for pharmaceutical manufacturing. It unifies quality management, regulatory compliance, and production operations into one intelligent system that powers your entire drug manufacturing lifecycle from raw materials to patient delivery.
